Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating restated by stock analysts at Royal Bank Of Canada in a report issued on Friday. They currently have a $210.00 price target on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 38.63% from the stock’s current price.

A number of other analysts also recently weighed in on the stock. Mizuho reduced their price target on shares of Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a “neutral” rating for the company in a report on Wednesday, May 31st. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 30th. Deutsche Bank AG reissued a “buy” rating and issued a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, July 4th. Cantor Fitzgerald reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, August 29th. Finally, Piper Jaffray Companies set a $182.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Friday, July 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $180.96.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 0.50% during midday trading on Friday, hitting $151.48. 439,864 shares of the stock were exchanged. The firm has a market cap of $9.10 billion, a P/E ratio of 23.33 and a beta of 1.13. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The stock’s 50 day moving average is $149.21 and its 200 day moving average is $149.94.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. During the same period last year, the company earned $2.67 earnings per share. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/15/jazz-pharmaceuticals-plc-jazz-stock-rating-reaffirmed-by-royal-bank-of-canada.html.

In other Jazz Pharmaceuticals PLC news, EVP Suzanne Sawochka Hooper sold 420 shares of the firm’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $160.00, for a total value of $67,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Paul Treacy sold 1,304 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $143.32, for a total transaction of $186,889.28. The disclosure for this sale can be found here. Insiders have sold a total of 8,717 shares of company stock valued at $1,346,617 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio increased its position in Jazz Pharmaceuticals PLC by 21.0% in the 3rd quarter. Strs Ohio now owns 215,160 shares of the specialty pharmaceutical company’s stock valued at $26,137,000 after acquiring an additional 37,392 shares in the last quarter. Renaissance Technologies LLC increased its position in Jazz Pharmaceuticals PLC by 1,044.1% in the 1st quarter. Renaissance Technologies LLC now owns 215,100 shares of the specialty pharmaceutical company’s stock valued at $28,081,000 after acquiring an additional 196,300 shares in the last quarter. OppenheimerFunds Inc. increased its position in Jazz Pharmaceuticals PLC by 54.1% in the 1st quarter. OppenheimerFunds Inc. now owns 150,840 shares of the specialty pharmaceutical company’s stock valued at $21,891,000 after acquiring an additional 52,960 shares in the last quarter. BlackRock Japan Co. Ltd increased its position in Jazz Pharmaceuticals PLC by 1.2% in the 3rd quarter. BlackRock Japan Co. Ltd now owns 77,214 shares of the specialty pharmaceutical company’s stock valued at $9,380,000 after acquiring an additional 909 shares in the last quarter. Finally, Tamarack Advisers LP acquired a new stake in Jazz Pharmaceuticals PLC in the 3rd quarter valued at about $12,082,000. Hedge funds and other institutional investors own 88.24% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.